AstraZeneca: CHMP recommends approval of Tagrisso in the EU
This recommendation is based on the results of a Phase III trial showing a 38% reduction in the risk of disease progression or death compared with Tagrisso monotherapy.
Median progression-free survival was 25.5 months with the chemotherapy combination, compared with 16.7 months with monotherapy.
"Today's news reinforces the importance of Tagrisso as a core therapy in EGFR-mutated lung cancer," commented Susan Galbraith, Executive Vice President, Oncology R&D at AstraZeneca.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction